Yan-Ping Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8497982/publications.pdf

Version: 2024-02-01

10	1,109	9	9
papers	citations	h-index	g-index
10	10	10	2132 citing authors
all docs	docs citations	times ranked	

#	Article	lF	CITATIONS
1	WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation. Molecular Cell, 2015, 57, 662-673.	9.7	242
2	Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Reports, 2016, 16, 2846-2854.	6.4	235
3	Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. Journal of Clinical Investigation, 2019, 129, 4316-4331.	8.2	143
4	Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nature Communications, 2018, 9, 508.	12.8	127
5	Oxidative Stress Activates SIRT2 to Deacetylate and Stimulate Phosphoglycerate Mutase. Cancer Research, 2014, 74, 3630-3642.	0.9	124
6	Vpr Targets TET2 for Degradation by CRL4VprBP E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication. Molecular Cell, 2018, 70, 961-970.e5.	9.7	77
7	Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nature Cell Biology, 2022, 24, 353-363.	10.3	67
8	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 , .	7.1	66
9	USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2. Science Advances, 2020, 6, .	10.3	28
10	Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis. Jbuon, 2021, 26, 1850-1861.	0.3	O